---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-029720"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2021-11-24T23:59:59+00:00"
generated_at: "2026-06-28T05:38:36.107148+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oncotelic reports Q3 net loss of $1.9M; provides JV, license, and clinical updates

## Summary
- Net loss: $1.86M (($0.00)/share) vs $1.99M (($0.02)/share) in Q3 2020; operating expenses rose to $1.8M.
- Secured $1.5M convertible note from GMP in Sep 2021 plus $0.5M in Oct 2021; JV with GMP for product portfolio at 35% stake.
- Exclusive license from Autotelic for patents; milestones up to $50M and 15% royalties on net sales.
- OT-101/IL-2 combo safety cohort completed; dose escalation above 140 mg/m² ongoing.
- OT-101 COVID-19 trial data locked; showed 4.5% mortality (OT-101) vs 20% placebo and improved overall survival.

## SEC filing metadata
- accession: 0001493152-21-029720
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2021-11-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315221029720/0001493152-21-029720-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315221029720/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-029720
- JSON: https://secwatch.observer/filing/0001493152-21-029720.json
- Plain text: https://secwatch.observer/filing/0001493152-21-029720.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.